Search clinical trials for: Y peginterferon alfa-2b

Total 856 results

Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Bausch Health Americas, Inc.

Terminated

Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C

Hepatitis C, Chronic

United States
University Hospital, Bordeaux
Schering-Plough

Completed

PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) (EADO)

Melanoma | Neoplasm Metastasis

France
Chang Gung Memorial Hospital
Merck Sharp & Dohme LLC

Unknown

36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8

Hepatitis C Infection

Taiwan
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) (START 4)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Withdrawn

Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) (PRACTICE)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

Hepatitis C | Hepatitis C, Chronic
National Taiwan University Hospital
PharmaEssentia

Recruiting

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Chronic Hepatitis B Virus Infection

Taiwan
Merck Sharp & Dohme LLC

Completed

PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)

Fibrosis | Liver Cirrhosis | Hepatitis | Hepatitis C, Chronic
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC; Novartis; Uppsala University Hospital

Terminated

Nilotinib Plus Pegylated Interferon-α2b in CML

Chronic Myeloid Leukemia

Netherlands, Denmark, Sweden, Finland, Norway
Merck Sharp & Dohme LLC

Completed

Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) (APEGIN)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Withdrawn

An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN) (PEGIMPACT)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) (RE-CHUT)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Completed

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

Liver Cirrhosis | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

Melanoma
Merck Sharp & Dohme LLC

Completed

Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)

Hepatitis C, Chronic
Emory University
CURE Childhood Cancer, Inc.

Completed

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Juvenile Pilocytic Astrocytomas | Optic Pathway Gliomas

United States
Third Affiliated Hospital, Sun Yat-Sen University

Unknown

Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection

Chronic Hepatitis b

China
Merck Sharp & Dohme LLC

Completed

Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Completed

Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)

Hepatitis C, Chronic
St. Jude Children's Research Hospital
Schering-Plough

Active, not recruiting

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Malignant Melanoma

United States
TCM Biotech International Corp.

Completed

The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection (TCM-700C)

Chronic Hepatitis C

Taiwan
Medtronic Corporate Technologies and New Ventures

Completed

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C (COPE-HCV)

Hepatitis C

United States
University of Michigan Rogel Cancer Center

Terminated

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

United States
Fundación de Investigación Biomédica - Hospital...
Haematology Service,

Unknown

Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)

Multiple Mieloma

Spain
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Essential Thrombocytopenia

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Completed

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Recurrence | Hematological Neoplasms

China
Novartis Pharmaceuticals
Human Genome Sciences Inc.

Terminated

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

Chronic Hepatitis B

Taiwan, Poland, China, Hong Kong, Thailand
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Hepatitis C, Chronic
National Institute of Diabetes and Digestive and...
Schering-Plough; Ortho Biotech Clinical Affairs, L.L.C.

Completed

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation (LADR)

Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)

Hepatitis C | Hepatitis C, Chronic
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Chronic Hepatitis C

United States, Spain, Canada, France, Australia, Italy, Israel, Poland, United Kingdom, Germany, Czech Republic, Romania, Austria, India, Puerto Rico
Chronic Liver Disease Foundation
Merck Sharp & Dohme LLC; SCRI Development Innovations, LLC

Completed

Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy (OPTIMAL)

Chronic Hepatitis C | Genotype 1

United States
University of Utah
Schering-Plough

Terminated

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

Gastrointestinal Stromal Tumors | Solid Tumors | Cancer Brain

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Essential Thrombocytopenia

China
Merck Sharp & Dohme LLC

Completed

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Hepatitis C
University of Modena and Reggio Emilia
Merck Sharp & Dohme LLC

Unknown

Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (MEN_BOC)

Menopause | Chronic Hepatitis C

Italy
National Taiwan University Hospital

Completed

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

COVID-19

Taiwan
National Institute of Allergy and Infectious Diseases...

Terminated

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Hepatitis | HIV/AIDS

United States

3

Subscribe